| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
GT Biopharma Inc (NASDAQ: GTBP)
GTBP Technical Analysis
5
| As on 9th Jun 2023 GTBP STOCK Price closed @ 0.35 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.58 & Strong Sell for SHORT-TERM with Stoploss of 3.03 we also expect STOCK to react on Following IMPORTANT LEVELS. |
GTBPSTOCK Price
| Open | 0.41 | Change | Price | % |
| High | 0.41 | 1 Day | -0.01 | -2.78 |
| Low | 0.31 | 1 Week | 0.13 | 59.09 |
| Close | 0.35 | 1 Month | -0.03 | -7.89 |
| Volume | 672341 | 1 Year | -3.42 | -90.72 |
| 52 Week High 3.77 | 52 Week Low 0.22 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| GTBP Daily Charts |
GTBP Intraday Charts |
Whats New @ Bazaartrend |
GTBP Free Analysis |
|
|
GTBP Important Levels Intraday
| RESISTANCE | 0.54 |
| RESISTANCE | 0.48 |
| RESISTANCE | 0.44 |
| RESISTANCE | 0.40 |
| SUPPORT | 0.30 |
| SUPPORT | 0.26 |
| SUPPORT | 0.22 |
| SUPPORT | 0.16 |
GTBP Forecast April 2024
| 4th UP Forecast | 2.8 |
| 3rd UP Forecast | 2.01 |
| 2nd UP Forecast | 1.53 |
| 1st UP Forecast | 1.04 |
| 1st DOWN Forecast | -0.34 |
| 2nd DOWN Forecast | -0.83 |
| 3rd DOWN Forecast | -1.31 |
| 4th DOWN Forecast | -2.1 |
GTBP Weekly Forecast
| 4th UP Forecast | 2.03 |
| 3rd UP Forecast | 1.49 |
| 2nd UP Forecast | 1.16 |
| 1st UP Forecast | 0.82 |
| 1st DOWN Forecast | -0.12 |
| 2nd DOWN Forecast | -0.46 |
| 3rd DOWN Forecast | -0.79 |
| 4th DOWN Forecast | -1.33 |
GTBP Forecast2024
| 4th UP Forecast | 7.5 |
| 3rd UP Forecast | 5.21 |
| 2nd UP Forecast | 3.79 |
| 1st UP Forecast | 2.37 |
| 1st DOWN Forecast | -1.67 |
| 2nd DOWN Forecast | -3.09 |
| 3rd DOWN Forecast | -4.51 |
| 4th DOWN Forecast | -6.8 |
GT Biopharma Inc ( NASDAQ USA Symbol : GTBP )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
GTBP Business Profile
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The company develops various immuno-oncology product candidates, including GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and other CD33+ hematopoietic malignancies; GTB-C3550, a follow-on to its lead candidates TriKE, GTB-3550; GTB-4550, a single-chain tri-specific single chain variable fragments (scFv) recombinant fusion protein conjugate for the treatment of PD-L1+ solid tumor cancers; and GTB-5550, a single-chain tri-specific scFv recombinant fusion protein conjugate for the treatment of B7H3+ solid tumor cancers. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology; and a collaboration agreement with Cytovance Biologics to provide development services for a TriKE therapeutic for the treatment of coronavirus infection. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Beverly Hills, California. Address: 9350 Wilshire Boulevard, Beverly Hills, CA, United States, 90212
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service